TNRC6A and infection: Gallichotte et al. used a genetically distinct DENV4/2-EDIII virus to show that DENV2 natural infection and vaccine sera primarily target a neutralizing epitope captured by mAb 2D22 that spans the DENV2 serotype-specific EDIII and conserved EDII residues and, to a lesser extent, EDI in most individuals (17).